JP5941040B2 - 副甲状腺ホルモン類似体およびその使用 - Google Patents

副甲状腺ホルモン類似体およびその使用 Download PDF

Info

Publication number
JP5941040B2
JP5941040B2 JP2013510293A JP2013510293A JP5941040B2 JP 5941040 B2 JP5941040 B2 JP 5941040B2 JP 2013510293 A JP2013510293 A JP 2013510293A JP 2013510293 A JP2013510293 A JP 2013510293A JP 5941040 B2 JP5941040 B2 JP 5941040B2
Authority
JP
Japan
Prior art keywords
pth
polypeptide
ala
aak
aib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013510293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526864A5 (enExample
JP2013526864A (ja
Inventor
トーマス ジェイ． ガーデラ
トーマス ジェイ． ガーデラ
ジョン ティー． ポッツ
ジョン ティー． ポッツ
ハラルド ジュプナー
ハラルド ジュプナー
岡崎　誠
誠 岡崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JP2013526864A publication Critical patent/JP2013526864A/ja
Publication of JP2013526864A5 publication Critical patent/JP2013526864A5/ja
Application granted granted Critical
Publication of JP5941040B2 publication Critical patent/JP5941040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/37—Parathyroid hormone [PTH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2013510293A 2010-05-13 2011-05-12 副甲状腺ホルモン類似体およびその使用 Active JP5941040B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33431910P 2010-05-13 2010-05-13
US61/334,319 2010-05-13
US41514110P 2010-11-18 2010-11-18
US61/415,141 2010-11-18
PCT/US2011/036222 WO2011143406A2 (en) 2010-05-13 2011-05-12 Parathyroid hormone analogs and uses thereof

Publications (3)

Publication Number Publication Date
JP2013526864A JP2013526864A (ja) 2013-06-27
JP2013526864A5 JP2013526864A5 (enExample) 2014-06-19
JP5941040B2 true JP5941040B2 (ja) 2016-06-29

Family

ID=44914975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510293A Active JP5941040B2 (ja) 2010-05-13 2011-05-12 副甲状腺ホルモン類似体およびその使用

Country Status (9)

Country Link
US (1) US9492508B2 (enExample)
EP (1) EP2569003B1 (enExample)
JP (1) JP5941040B2 (enExample)
KR (1) KR101900078B1 (enExample)
CN (1) CN103002906B (enExample)
BR (1) BR112012028949B1 (enExample)
MX (1) MX358161B (enExample)
RU (1) RU2604809C2 (enExample)
WO (1) WO2011143406A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002906B (zh) 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用
US20160175401A1 (en) 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
BR112018017091A2 (pt) 2016-03-01 2019-01-02 Ascendis Pharma Bone Diseases As profármacos de pth
NZ751745A (en) 2016-09-29 2023-05-26 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
ES3012647T3 (en) 2016-09-29 2025-04-09 Ascendis Pharma Bone Diseases As Controlled-release pth compounds
CN109789189B (zh) * 2016-09-29 2024-01-23 阿森迪斯药物骨疾病股份有限公司 控释pth化合物的剂量方案
GB201706781D0 (en) 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
EP3655104A4 (en) 2017-07-15 2021-03-17 The Regents of the University of California CATHEPSIN K OSTEOADSORBANT FLUOROGENIC SUBSTRATE FOR IMAGING OF OSTEOCLAST ACTIVITY AND MIGRATION
WO2019178462A1 (en) * 2018-03-16 2019-09-19 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
KR102891411B1 (ko) 2019-02-11 2025-11-25 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
US12344649B2 (en) 2019-08-09 2025-07-01 Flagship Pioneering Innovations Vi, Llc Modulators of parathyroid hormone receptor (PTHR1)
WO2021030196A1 (en) * 2019-08-09 2021-02-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release
US20230042670A1 (en) * 2020-01-13 2023-02-09 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism Treatment
CN116847870A (zh) * 2020-09-28 2023-10-03 阿森迪斯药物骨疾病股份有限公司 甲状旁腺功能减退症患者身体及心理健康的改善
EP4217004A1 (en) * 2020-09-28 2023-08-02 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
JP2025534350A (ja) 2022-09-30 2025-10-15 エクステンド バイオサイエンシズ インコーポレーテッド 長時間作用型副甲状腺ホルモン
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4849338A (en) 1982-07-16 1989-07-18 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4843000A (en) 1979-12-26 1989-06-27 Syntex (U.S.A.) Inc. Simultaneous calibration heterogeneous immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JPS5896052A (ja) 1981-11-30 1983-06-07 Toyo Jozo Co Ltd 高活性ｈ−ＰＴＨ（１−３４）アミドの製造法
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4518526A (en) 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
JPS59204159A (ja) 1983-04-28 1984-11-19 Toyo Jozo Co Ltd 〔Ｍｅｔ（Ｏ）↑８’↑１↑８〕ｈＰＴＨ−（１−３４）ペプチド
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
EP0232262A4 (en) 1985-08-15 1989-09-19 Stauffer Chemical Co TRYPTOPHANE GENERATING MICROORGANISM.
US5010010A (en) 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
US4771124A (en) 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
US5527772A (en) 1987-10-20 1996-06-18 Holick; Michael F. Regulation of cell proliferation and differentiation using peptides
US5605815A (en) 1988-03-14 1997-02-25 Yale University Nucleic acids encoding and expression of parathyroid hormone-like peptide
DE68921665T2 (de) 1988-05-09 1995-09-21 Merck & Co Inc Hemmer vom flüssigen kalziumerhöhenden Faktor.
US5217896A (en) 1988-12-30 1993-06-08 Oncogene Science, Inc. Monoclonal antibodies recognizing parathyroid hormone-like protein
EP0448650A4 (en) 1989-02-01 1992-05-13 The General Hospital Corporation Herpes simplex virus type i expression vector
WO1991005050A1 (en) 1989-09-29 1991-04-18 Her Majesty In Right Of Canada As Represented By The National Research Council Of Canada Synthesis of mature human parathyroid hormone
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
IT1238348B (it) 1989-11-16 1993-07-13 Processo per la preparazione di costrutti genetici per l'espressione del fattore di crescita nervoso in cellule eucariote.
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5648270A (en) 1995-02-06 1997-07-15 Molecular Probes, Inc. Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
US5453517A (en) 1992-02-25 1995-09-26 Molecular Probes, Inc. Reactive derivatives of bapta used to make ion-selective chelators
US5405975A (en) 1993-03-29 1995-04-11 Molecular Probes, Inc. Fluorescent ion-selective diaryldiaza crown ether conjugates
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
US5433896A (en) 1994-05-20 1995-07-18 Molecular Probes, Inc. Dibenzopyrrometheneboron difluoride dyes
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5459276A (en) 1994-05-20 1995-10-17 Molecular Probes, Inc. Benzazolylcoumarin-based ion indicators for heavy metals
US5266490A (en) 1991-03-28 1993-11-30 Regeneron Pharmaceuticals, Inc. Mammalian expression vector
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
JPH0532696A (ja) 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
JP3464796B2 (ja) 1991-04-05 2003-11-10 ザ ジェネラル ホスピタル コーポレーション 副甲状腺ホルモンのレセプターとそれをコードしているｄｎａ
US7132260B2 (en) 1991-04-05 2006-11-07 The General Hospital Corporation DNA encoding parathyroid hormone receptor
US5261686A (en) 1992-04-06 1993-11-16 Buckler Clive E Semi-recumbent
US7150974B1 (en) 1991-04-05 2006-12-19 The General Hospital Corporation Parathyroid hormone receptor binding method
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
AU2807892A (en) 1991-10-10 1993-05-03 Peter K.T. Pang Parathyroid hormone analogues and use in osteoporosis treatment
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
DE4138621A1 (de) 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
JPH07502507A (ja) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
US5434246A (en) 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5814603A (en) 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5871486A (en) 1993-01-21 1999-02-16 Acumed, Inc. Variable pitch bone screw
WO1994029442A2 (en) 1993-06-14 1994-12-22 Basf Aktiengesellschaft Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5496801A (en) 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
CA2126132A1 (en) 1994-06-17 1995-12-18 Witold Neugebauer Peptide synthesis on chitosan
US5836905A (en) 1994-06-20 1998-11-17 Lemelson; Jerome H. Apparatus and methods for gene therapy
US5556940A (en) 1994-06-20 1996-09-17 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CO4410206A1 (es) 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
DE4434551A1 (de) 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
SK76797A3 (en) 1994-12-22 1998-02-04 Astra Ab Therapeutic preparation for inhalation containing parathyroid hormone, pth
US5717062A (en) 1995-06-07 1998-02-10 Beth Israel Hospital Association Cyclic analogs of PTH and PTHrP
JPH09157294A (ja) 1995-06-15 1997-06-17 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
CA2178894A1 (en) 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
WO1998004591A1 (en) 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
ATE253078T1 (de) * 1996-08-02 2003-11-15 Ca Nat Research Council Analoge des parathormons zur behandlung der osteoporose
US5917123A (en) 1997-03-14 1999-06-29 University Of Pittsburgh Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region
CA2290443A1 (en) * 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Peptide parathyroid hormone analogs
US6183974B1 (en) 1997-07-31 2001-02-06 The General Hospital Corporation Screening assays for G protein coupled receptor agonists and antagonists
CA2306344A1 (en) 1997-10-14 1999-04-22 Masahiko Sato Method of building and maintaining bone
AU3673699A (en) 1998-05-05 1999-11-23 Beth Israel Deaconess Medical Center Pth2 receptor selective compounds
AU1447600A (en) 1998-10-22 2000-05-08 Thomas J. Gardella Bioactive peptides and peptide derivatives of parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp)
WO2000031137A1 (en) 1998-11-25 2000-06-02 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
EP1133560B1 (en) 1998-11-25 2010-02-17 The General Hospital Corporation Human parathyroid hormone modifications, preparation and use
WO2000032771A1 (en) 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
ATE308609T1 (de) 1998-12-31 2005-11-15 Gen Hospital Corp Pth rezeptor und testverfahren unter verwendung desselben
WO2000039278A2 (en) 1998-12-31 2000-07-06 The General Hospital Corporation Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP4723144B2 (ja) 1999-09-29 2011-07-13 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
AU2002241899A1 (en) 2001-01-17 2002-09-12 Gardella, Thomas, J. Tip39 polypeptides
CA2454275C (en) 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
MXPA04006728A (es) 2002-01-10 2005-08-19 Osteotrophin Llc Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos.
JP4541899B2 (ja) 2003-01-24 2010-09-08 ザ ジェネラル ホスピタル コーポレイション ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2201960A1 (en) 2003-03-19 2010-06-30 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
JP4871128B2 (ja) 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
CA2504920C (en) 2004-05-14 2014-04-01 Euroscreen S.A. Ligand for g-protein coupled receptor fprl2 and uses thereof
CA2580281A1 (en) 2004-09-16 2006-03-30 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US8143374B2 (en) 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX353986B (es) * 2007-08-01 2017-11-06 Massachusetts Gen Hospital Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
CN103002906B (zh) 2010-05-13 2017-12-29 总医院有限公司 甲状旁腺激素类似物及其应用

Also Published As

Publication number Publication date
EP2569003A2 (en) 2013-03-20
WO2011143406A3 (en) 2011-12-22
MX2012013232A (es) 2013-05-01
US20130116180A1 (en) 2013-05-09
CN103002906B (zh) 2017-12-29
KR20140031778A (ko) 2014-03-13
US9492508B2 (en) 2016-11-15
BR112012028949B1 (pt) 2020-11-17
MX358161B (es) 2018-08-06
WO2011143406A2 (en) 2011-11-17
CN103002906A (zh) 2013-03-27
RU2604809C2 (ru) 2016-12-10
EP2569003B1 (en) 2017-10-25
KR101900078B1 (ko) 2018-09-18
RU2012153768A (ru) 2014-06-20
EP2569003A4 (en) 2013-11-27
JP2013526864A (ja) 2013-06-27

Similar Documents

Publication Publication Date Title
JP5941040B2 (ja) 副甲状腺ホルモン類似体およびその使用
AU2020202573B2 (en) Use of long-acting GLP-1 peptides
US8603977B2 (en) Conformationally constrained parathyroid hormone (PTH) analogs
JP4026854B2 (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
JP4541899B2 (ja) ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ
JP5711966B2 (ja) Ｇタンパク質共役受容体および関連組成物を使用するスクリーニング方法
JP4334480B2 (ja) α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
AU2002339843A1 (en) Conformationally constrained parathyroid hormone (PTH) analogs
JP4871128B2 (ja) 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
HK1180229B (en) Parathyroid hormone analogs and uses thereof
HK1180229A (en) Parathyroid hormone analogs and uses thereof
WO2025250793A1 (en) Parathyroid hormone polypeptide conjugates and methods of their use
ES2767705T3 (es) Nuevos análogos de glucagón
Hinke Modulation of insulinotropic hormone bioactivity with a focus on clucose-dependent insulinotropic polipeptide (GIP) and its receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140428

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160519

R150 Certificate of patent or registration of utility model

Ref document number: 5941040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250